Relmada Therapeutics, Inc. (RLMD) stock
RLMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$4.21+0.05 (+1.20%)
Close on Nov 13, 2026Market cap $449.08MP/E –Yield –
Earnings
Relmada Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Mar 19, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.12
-$0.30 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Relmada Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 19, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 12, 2026after the close | – | – | -$0.12 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 6, 2026during market hours | – | – | -$0.11 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 12, 2026during market hours | – | – | -$0.22 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 20, 2026during market hours | – | – | -$0.27 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 13, 2025during market hours | – | – | -$0.30 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025during market hours | – | – | -$0.30 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 27, 2025during market hours | – | – | -$0.62 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 19, 2024during market hours | – | – | -$0.84 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 8, 2023during market hours | – | – | -$0.73 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 8, 2023during market hours | – | – | -$0.84 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 11, 2023during market hours | – | – | -$0.87 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 23, 2023during market hours | – | – | $1.28 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 10, 2022during market hours | – | – | -$1.31 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 5, 2022during market hours | – | – | -$1.40 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 23, 2022during market hours | – | – | -$1.80 | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Relmada Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Relmada Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Relmada Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Update
- Results
- Results
- Results
- Results
- Update
- Update
- Update
- Results
- Results
- Update
See a number that looks wrong?